SpliSense
Manufacturing · Israel · 11-50 Employees
View Company Info for Free
Overview
Headquarters
The Hebrew University of Jerusalem Edmon...Phone Number
+972 528367731Website
www.splisense.comRevenue
<$5 MillionIndustry
About SpliSense
SpliSense Org Chart
Vice President, Clinical & Regulatory Affairs
Is SpliSense your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if SpliSense had a recent Job posting/layoffs
Earning: See what the market has to say on SpliSense recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at SpliSense
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Check out if SpliSense is spiking on competitors!
Product Launch: Get notified when SpliSense launches new products
Check if SpliSense has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once SpliSense has new funding data
SpliSense, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Reach out to Masked Content who joined SpliSense as Masked Content
Find 3 more new buyers
Company Profile Activity
Activity Insights
SpliSense is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
SpliSense is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about SpliSense.
SpliSense financials insights
Gather financial insights about SpliSense, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
Series B
$28.5M
SpliSense Tech Stack
A closer look at the technologies used by SpliSense
SpliSense News & Media
SpliSense Receives FDA Fast Track Designation for SPL84 for the Treatment of Cystic Fibrosis
JERUSALEM, May 29, 2024 /PRNewswire/ -- SpliSense, a clinical-stage biotechnology company focused on the development of transformative RNA-based therapies for pulmonary diseases including cystic fibrosis (CF), muco-obstructive diseases like COPD, asthma and NCFB and idiopathic pulmonary...SpliSense Announces FDA Clearance of Investigational New Drug Application for Phase 2 Initiation of SPL84 for the Treatment of Cystic Fibrosis
- Funding secured from CF Foundation and current investors for SPL84 Phase 2 study - - Two additional early-stage candidates expected to commence Phase 1-2a studies over the next 12 months – JERUSALEM, April 3, 2024 /PRNewswire/ -- SpliSense, a clinical-stage biotechnology company focused...SpliSense Successfully Completed Phase 1 Study of SPL84, RNA-Based Therapy, for the Treatment of Cystic Fibrosis
Phase 2 efficacy study to be initiated in H1 2024 New data published in Nucleic Acid Therapeutics demonstrate broad distribution, as well as cell and nucleus penetration of SPL84 in lungs of animal models, overcoming hyper-concentrated mucus barriers, thus leading to specific and targeted...SpliSense Initiates Phase 1/2 Study of SPL84, RNA-Based Therapy, for the Treatment of Cystic Fibrosis
JERUSALEM, Dec. 14, 2022 /PRNewswire/ -- SpliSense, a biopharmaceutical company developing transformative RNA-based therapies for pulmonary diseases including cystic fibrosis (CF), muco-obstructive diseases and idiopathic pulmonary fibrosis (IPF), today announced that it has initiated a...
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Frequently Asked Questions Regarding SpliSense
Based in Jerusalem, Israel. SpliSense is a biopharmaceutical company focused on transformative mRNA-altering treatments targeting unmet needs in genetic pulmonary diseases. The company was founded in 2016.... Read More